NetworkNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) Announces Board Appointment of Psychedelic Medicine Expert
Clearmind Medicine (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that Mark Haden has joined its scientific advisory board (“SAB”). The SAB’s initial focus will be providing guidance on the company’s request for an Investigational New Drug review from the U.S. Food and Drug Administration (“FDA”) for MEAI, for treating alcohol use disorder (“AUD”). Haden is a recognized leader in the field, having spent his career working to advance the use of psychedelics in medicine. He currently serves as director of clinical…